Novo Nordisk ASMEX:NOVOBN +3.85%79 Interest Coverage is 17.04 as of Mar. 2026, which is 91% below its 10-year median of 200.42. GuruFocus rates MEX:NOVOBN with a GF Score™ of 79/100 and a GF Value™ of MXN2,387.36 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 685 Drug Manufacturers companies, Novo Nordisk AS ranks better than 73.43% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Novo Nordisk AS's
Operating Income
for the
three
months ended in Mar. 2026 was MXN166,284 Mil. Novo Nordisk AS's Interest Expense for the
three
months ended in Mar. 2026 was MXN-9,759 Mil.
Novo Nordisk AS's interest coverage for the quarter that ended in Mar. 2026 was 17.04.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Novo Nordisk AS's Interest Coverage or its related term are showing as below:
MEX:NOVOBN'
s Interest Coverage Range Over the Past 10 Years
Min: 30.34 Med: 200.42 Max: 745.11
Current: 58.85
MEX:NOVOBN's Interest Coverage is ranked better than 73.43% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs MEX:NOVOBN: 58.85
Novo Nordisk AS (MEX:NOVOBN) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Novo Nordisk AS Interest Coverage Related Terms
Novo Nordisk AS Interest Coverage Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MEX:NOVOBN vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (MEX:NOVOBN) has a Interest Coverage of 17.04 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Novo Nordisk AS and its competitors. This is 91% below median its historical median of 200.42. Over the past decade, Novo Nordisk AS's Interest Coverage has ranged from 30.34 to 745.11. According to the industry distribution chart, Novo Nordisk AS ranks #182 out of 685 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is Novo Nordisk AS's Interest Coverage too high?
Novo Nordisk AS's current Interest Coverage of 17.04 is 91% below median its 10-year median of 200.42. Over the past 10 years, this metric has ranged from a low of 30.34 to a high of 745.11. The Drug Manufacturers industry median Interest Coverage is 12.78. Novo Nordisk AS's value of 17.04 is 33.3% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #182 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #182 out of 685 companies for Interest Coverage. This puts Novo Nordisk AS in the upper half of its industry. The industry median Interest Coverage is 12.78. Novo Nordisk AS's value of 17.04 is 33.3% above this benchmark. Historically, Novo Nordisk AS's own Interest Coverage has ranged from 30.34 to 745.11 over the past decade. While the company's 10-year median is 200.42 vs. the industry median of 12.78, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Interest Coverage of 17.04 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Interest Coverage is 17.04, which is 91% below median its own 10-year median of 200.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current Interest Coverage is 17.04, which is 91% below median its 10-year median of 200.42 and 33.3% above the Drug Manufacturers industry median of 12.78. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current Interest Coverage is 17.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NOVOBN:
Interest Coverage: 17.04 (91% below median its 10-year median of 200.42)
GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
Industry Position: 33.3% above the Drug Manufacturers median (#182 of 685)
No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score
Get the complete analysis for MEX:NOVOBN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NOVOBN has been successfully added to your 
